NEW YORK, Dec. 14 – Oxford GlycoSciences has extended for another year a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS said Friday.
Under the terms of the renewed agreement, OGS of Oxford, UK, will continue to use its proteomics technology to identify biomarkers in areas of interest to Pfizer. In exchange, Pfizer will provide additional research funding.
The deal, which was first penned in 1998, was last extended one year ago. At the time Pfizer also took a small stake in OGS.
Pfizer has also renewed its licenses to the OGS human serum and cerebrospinal fluid expression databases and to PC Rosetta, a data analysis software tool.
OGS has the right to commercialize any diagnostic products arising from the collaboration.